THALOMID
LOE ApproachingNDAORALCAPSULE
Approved
May 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
THALOMID by Bristol Myers Squibb is understood. First approved in 2006.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THALOMID (thalidomide) is an oral immunomodulatory agent approved in 2006 for multiple myeloma and erythema nodosum leprosum (ENL). The drug works through immune system modulation and anti-angiogenic mechanisms, enhancing T-cell proliferation while inhibiting tumor necrosis factor-alpha production.
$0.019BPart D
LOE ApproachingWith LOE approaching and minimal Part D claims, this product faces declining lifecycle pressures; commercial team may be right-sizing or transitioning focus to newer pipeline assets.
Mechanism of Action
understood. Cellular activities of thalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. THALOMID possesses immunomodulatory, anti-inflammatory and antiangiogenic properties. Available data from in vitro studies and clinical trials…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on THALOMID at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.